期刊文献+

靶向ABCG2的RNA干扰逆转乳腺癌球囊细胞化疗耐药的研究 被引量:2

RNA interference targeting ABCG2 reverses chemotherapy resistance in mamosphere cell of breast cancer
下载PDF
导出
摘要 目的通过靶向ABCG2的RNA干扰逆转乳腺癌球囊细胞化疗耐药。方法以ABCG2为靶点,设计ABCG2-siRNA,构建ABCG2干扰慢病毒载体并包装好病毒,稳定转染到筛选好的MCF-7球囊细胞中,Western Blot方法检测ABCG2的表达情况,MTT法检测RNAi沉默ABCG2基因对球囊细胞的增殖抑制作用,同时流式细胞术检测RNAi沉默ABCG2对MCF-7球囊细胞在耐药情况下的细胞周期变化和凋亡状况。结果 ABCG2干扰慢病毒载体成功构建并包装病毒,建立起ABCG2稳定沉默的MCF-7乳腺癌球囊细胞系。Western Blot显示球囊细胞中高表达的ABCG2,在RNAi沉默后表达下降;MTT结果显示,在5-Fu的作用下的MCF-7贴壁细胞抑制率高于MCF-7球囊细胞,而沉默ABCG2的MCF-7球囊细胞其抑制率会随着5-Fu量的增加而增高;流式细胞仪也显示球囊细胞大多处于G0/G1期,加入5-Fu和沉默ABCG2后,处于G0/G1期细胞数会增加,凋亡率会明显增加。结论乳腺癌球囊细胞高表达ABCG2蛋白,其5-Fu耐药性高于亲本MCF-7细胞,沉默ABCG2后能够增加球囊细胞在5-Fu的作用下的细胞抑制率及凋亡率,从而逆转对5-Fu的耐药性。 Objective To investigate the effect of RNA interference targeting ABCG2 gene on reverse chemotherapy resistance of mamosphere cell of breast cancer. Methods ABCG2-siRNA sequence was designed and inserted into lentiviral vector and virus was packaged, then a stable ABCG2-silenced MCF-7 mamosphere cell lines was estabhshed. The expression level of ABCG2 was detected by Western blot. The proliferation was measured by MTTassay in MCF-7 mamosphere cells after RNA interference. Flow cytometry was performed to assess the cell cycle and apoptotic rate. Results Western Blot showed that ABCG2 was highly expressed in the mamosphere cells, and the expression decreased concurrently after RNAi silenced ABCG2. MTr showed that inhibition rate of MCF-7 adherent cells was higher than that of MCF-7 mamosphere cells of in the presence of 5-Fu, and the inhibition rate increased as the concentration of 5-FU increased in ABCG2-silenced mamosphere cells. Flow cytometry also showed that most mamosphere cells were in Go/G1 phase, and the number of mamosphere cells in G0/G1 phase and apoptosis were elevated with increasing concentration of 5-Fu or ABCG2 gene blockage. Conclusion ABCG2 protein highly expressed in breast cancer mamosphere cells. The inhibition of ABCG2 gene expression could significantly increase the cell inhibition rate and the apoptosis rate in mamosphere cell, and reverse its resistance to 5-Fu.
出处 《岭南现代临床外科》 2014年第1期8-12,共5页 Lingnan Modern Clinics in Surgery
基金 国家自然科学基金(编号:81372819) 教育部博士点基金(编号:20120171110075) 中山大学青年教师重点培育项目(编号:13ykzd14)
关键词 乳腺癌 球囊细胞 ABCG2 RNA干扰 药物耐受 Breast cancer Mamosphere cell ABCG2 RNA interference Drug resistance
  • 相关文献

参考文献11

  • 1白敬超,张瑾.乳腺癌干细胞研究进展[J].中国全科医学,2012,15(35):4147-4150. 被引量:3
  • 2Polyak K,Hahn WC. Roots and stems:stem cells in cancer[J].{H}Nature Medicine,2006,(03):296-300.
  • 3Al-Hajj M. Cancer stem cells and oncology therapeutics[J].Curt Opin Oncol,2007,(01):61-64.
  • 4Yu F,Yao H,Zhu P. let-7 regulates self renewal and tumorigenicity of breast cancer cells[J].{H}CELL,2007,(06):1109-1123.
  • 5Hirose H,Yamamoto H,Miyoshi N. Cancer stem cells in solid tumors[J].{H}Gan To Kagaku Ryoho,2010,(13):2809-2812.
  • 6Ponti D,Costa A,Zaffaroni N. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/ progenitor cell properties[J].{H}CANCER RESEARCH,2005,(13):5506-5511.
  • 7Mueller MT,Hermann PC,Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis[J].Front Biosci (Elite Ed),2010.602-613.
  • 8Leonard GD,Fojo T,Bates SE. The role of ABC transporters in clinical practice[J].{H}Oncologist(the)t,2003,(05):411-424.
  • 9王英泽,段相林,李永福,梁兴杰.半分子转运蛋白ABCG2的肿瘤多药耐药性研究及其应用[J].生物化学与生物物理进展,2009,36(12):1523-1529. 被引量:7
  • 10Nguyen NP,Almeida FS,Chi A. Molecular biology of breast cancer stem cells:potential clinical applications[J].{H}Cancer Treatment Reviews,2010,(06):485-491.

二级参考文献58

  • 1Liang X J, Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets, 2006, 7(8): 911 -921.
  • 2Doyle L A, Yang W, Abruzzo L V, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.
  • 3Allikrnets R, Schriml L M, Hutchinson A, et al. A human placentaspecific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res, 1998, 58(23): 5337-5339.
  • 4Brangi M, Litrnan T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res, 1999, 59(23): 5938-5946.
  • 5Merino G, van Herwaarden A E, Wagenaar E, et al. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol, 2005, 67(5): 1765-1771.
  • 6Szatmari I, Vamosi G, Brazda P, et al. Peroxisome proliferatoractivated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem, 2006, 281 (33): 23812-23823.
  • 7Wang H, Lee E W, Zhou L, et al. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol, 2008, 73(3): 845 -854.
  • 8Yin L, Castagnino P, Assoian R K. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res, 2008, 68(3): 800-807.
  • 9Evseenko D A, Paxton J W, Keelan J A. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos, 2007, 35(4): 595-601.
  • 10Yoshikawa M, Ikegami Y, Hayasaka S, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer, 2004, 110(6): 921-927.

共引文献8

同被引文献26

  • 1吴在德,吴肇汉.外科学[M].7版.北京:人民卫生出版社,2007:305-306.
  • 2So WK, Marsh G, Ling WM, et al. The symptom cluster of fa- tigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multi- center study[J]. Oncol Nurs Forum, 2009,36(4) :E205-214.
  • 3Bergamaschi A, Madak-EMogan Z, Kim Y, et al. The forkhead tin- scription factor FOXM1 promotes endocrine resistance and invasive- ness in estrogen receptor-positive breast cancer by expansion of stem- like cancer cells[J]. Breast Cancer Res, 2014,16(5) :436.
  • 4Pelicano H, Zhang W, Liu J, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of roTOR path- way and therapeutic potential [ J ]. Breast Cancer Res, 2014, 16(5) :434.
  • 5Miura D, Yoneymna K, Furuhata Y, et al. Paelitaxel enhances zaati- body-dependent cell-medialed eytotoxieity of trastuzumab by rapid re- cruitment of natural killer cells in HER2-positive breast earteer[J]. J Nippon Med Seh, 2014,81 (4) :211-220.
  • 6Bjrneklett HG, Lindemalm C, Rosenblad A, et al. A randomised controlled trial of support group intervention after breast cancer treatment., results on inxiety and depression [ J ]. Acta Oncol, 2012,51 (2) :198-207.
  • 7Ahem TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities[ J]. Lancet Oncol, 2014, 15(10) :e461 468.
  • 8Argov M, Kashi R, Peer D, et al. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhancestherapeutic responses comparable to an aggressive bevaci- zumab regimen[ J]. Cancer Lett, 2009,274 ( 1 ) : 118-125.
  • 9Kurzrock R, Gabrail N, Chandhasin C, et al. Safety, pharmacoki- neties, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paelitaxel, in patients with advanced solid tumors [ J]. Mol Cancer Ther, 2012,11 (2) : 308-316.
  • 10Knramochi H, Tanaka K, Oh D, et al. Thymidylate syntbase poly- morphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients [ J ]. Int J Oncol, 2008,32( 1 ) :201-208.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部